Listed

Syndax Pharmaceuticals Inc

SNDXNasdaqCIK 1395937HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$72.8m, Q2 FY2026
Operating income−$40.0m, Q2 FY2026
Net income−$49.4m, Q2 FY2026
Syndax Pharmaceuticals Inc, income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.0Revenue, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-05, accession 0000950170-24-121439.Report this figure0.0Revenue, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-076536. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-05, accession 0000950170-25-063518.Report this figure3.5Revenue, Q2 FY2024, three months to 2024-06-30$3.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-04, accession 0000950170-25-101985.Report this figure12.5Revenue, Q3 FY2024, three months to 2024-09-30$12.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure7.7Revenue, Q4 FY2024, three months to 2024-12-31$7.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-076536. Derived: 12-month figure less the 9-month figure.Report this figure20.0Revenue, Q1 FY2025, three months to 2025-03-31$20.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure38.0Revenue, Q2 FY2025, three months to 2025-06-30$38.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure45.9Revenue, Q3 FY2025, three months to 2025-09-30$45.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure68.7Revenue, Q4 FY2025, three months to 2025-12-31$68.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-076536. Derived: 12-month figure less the 9-month figure.Report this figure64.9Revenue, Q1 FY2026, three months to 2026-03-31$64.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure72.8Revenue, Q2 FY2026, three months to 2026-06-30$72.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure
Research and development$m39.1Research and development, Q3 FY2023, three months to 2023-09-30$39.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-05, accession 0000950170-24-121439.Report this figure55.1Research and development, Q4 FY2023, three months to 2023-12-31$55.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001193125-26-076536. Derived: 12-month figure less the 9-month figure.Report this figure56.5Research and development, Q1 FY2024, three months to 2024-03-31$56.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-05, accession 0000950170-25-063518.Report this figure48.7Research and development, Q2 FY2024, three months to 2024-06-30$48.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-04, accession 0000950170-25-101985.Report this figure71.0Research and development, Q3 FY2024, three months to 2024-09-30$71.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure65.5Research and development, Q4 FY2024, three months to 2024-12-31$65.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001193125-26-076536. Derived: 12-month figure less the 9-month figure.Report this figure61.6Research and development, Q1 FY2025, three months to 2025-03-31$61.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure62.2Research and development, Q2 FY2025, three months to 2025-06-30$62.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure56.3Research and development, Q3 FY2025, three months to 2025-09-30$56.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure78.6Research and development, Q4 FY2025, three months to 2025-12-31$78.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001193125-26-076536. Derived: 12-month figure less the 9-month figure.Report this figure58.8Research and development, Q1 FY2026, three months to 2026-03-31$58.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure68.0Research and development, Q2 FY2026, three months to 2026-06-30$68.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure
Operating income$m(56.4)Operating income, Q3 FY2023, three months to 2023-09-30−$56.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-05, accession 0000950170-24-121439.Report this figure(77.9)Operating income, Q4 FY2023, three months to 2023-12-31−$77.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076536. Derived: 12-month figure less the 9-month figure.Report this figure(79.5)Operating income, Q1 FY2024, three months to 2024-03-31−$79.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-05, accession 0000950170-25-063518.Report this figure(74.2)Operating income, Q2 FY2024, three months to 2024-06-30−$74.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-04, accession 0000950170-25-101985.Report this figure(89.6)Operating income, Q3 FY2024, three months to 2024-09-30−$89.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure(96.4)Operating income, Q4 FY2024, three months to 2024-12-31−$96.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076536. Derived: 12-month figure less the 9-month figure.Report this figure(83.8)Operating income, Q1 FY2025, three months to 2025-03-31−$83.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure(69.4)Operating income, Q2 FY2025, three months to 2025-06-30−$69.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure(57.4)Operating income, Q3 FY2025, three months to 2025-09-30−$57.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure(62.5)Operating income, Q4 FY2025, three months to 2025-12-31−$62.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076536. Derived: 12-month figure less the 9-month figure.Report this figure(34.2)Operating income, Q1 FY2026, three months to 2026-03-31−$34.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure(40.0)Operating income, Q2 FY2026, three months to 2026-06-30−$40.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure
Interest expense$m0.1Interest expense, Q3 FY2023, three months to 2023-09-30$70.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2023-11-02, accession 0000950170-23-058165.Report this figure0.1Interest expense, Q4 FY2023, three months to 2023-12-31$63.0k. XBRL concept us-gaap:InterestExpense. 10-K filed 2024-02-27, accession 0000950170-24-021253. Derived: 12-month figure less the 9-month figure.Report this figure0.1Interest expense, Q1 FY2024, three months to 2024-03-31$55.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-05-08, accession 0000950170-24-055053.Report this figure0.0Interest expense, Q2 FY2024, three months to 2024-06-30$45.0k. XBRL concept us-gaap:InterestExpense. 10-Q filed 2024-08-01, accession 0000950170-24-089241.Report this figure0.0Interest expense, Q3 FY2024, three months to 2024-09-30$23.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure(0.1)Interest expense, Q4 FY2024, three months to 2024-12-31−$124.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-02-26, accession 0001193125-26-076536. Derived: 12-month figure less the 9-month figure.Report this figure0.0Interest expense, Q1 FY2025, three months to 2025-03-31$2.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure0.0Interest expense, Q2 FY2025, three months to 2025-06-30$4.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure0.0Interest expense, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure0.0Interest expense, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-02-26, accession 0001193125-26-076536. Derived: 12-month figure less the 9-month figure.Report this figure0.0Interest expense, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure0.0Interest expense, Q2 FY2026, three months to 2026-06-30$2.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure
Income tax$mnot reportednot reported0.0Income tax, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-05, accession 0000950170-25-063518.Report this figure0.0Income tax, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-04, accession 0000950170-25-101985. Derived: 6-month figure less the 3-month figure.Report this figure0.0Income tax, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-03, accession 0001193125-25-262521. Derived: 9-month figure less the 6-month figure.Report this figurenot reported0.0Income tax, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure0.0Income tax, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-04, accession 0001193125-26-332750. Derived: 6-month figure less the 3-month figure.Report this figure0.0Income tax, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-03, accession 0001193125-25-262521. Derived: 9-month figure less the 6-month figure.Report this figure0.4Income tax, Q4 FY2025, three months to 2025-12-31$433.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-26, accession 0001193125-26-076536. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure0.0Income tax, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-04, accession 0001193125-26-332750. Derived: 6-month figure less the 3-month figure.Report this figure
Net income$m(51.1)Net income, Q3 FY2023, three months to 2023-09-30−$51.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-05, accession 0000950170-24-121439.Report this figure(72.5)Net income, Q4 FY2023, three months to 2023-12-31−$72.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076536. Derived: 12-month figure less the 9-month figure.Report this figure(72.4)Net income, Q1 FY2024, three months to 2024-03-31−$72.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure(68.1)Net income, Q2 FY2024, three months to 2024-06-30−$68.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure(84.1)Net income, Q3 FY2024, three months to 2024-09-30−$84.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure(94.2)Net income, Q4 FY2024, three months to 2024-12-31−$94.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076536. Derived: 12-month figure less the 9-month figure.Report this figure(84.8)Net income, Q1 FY2025, three months to 2025-03-31−$84.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure(71.8)Net income, Q2 FY2025, three months to 2025-06-30−$71.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure(60.7)Net income, Q3 FY2025, three months to 2025-09-30−$60.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure(68.0)Net income, Q4 FY2025, three months to 2025-12-31−$68.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076536. Derived: 12-month figure less the 9-month figure.Report this figure(42.7)Net income, Q1 FY2026, three months to 2026-03-31−$42.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure(49.4)Net income, Q2 FY2026, three months to 2026-06-30−$49.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure
Diluted EPS$ per share(0.73)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.73 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-05, accession 0000950170-24-121439.Report this figurenot reported(0.85)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.85 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-05, accession 0000950170-25-063518.Report this figure(0.80)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.80 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-04, accession 0000950170-25-101985.Report this figure(0.98)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.98 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figurenot reported(0.98)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.98 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure(0.83)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.83 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure(0.70)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.70 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figurenot reported(0.48)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.48 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure(0.55)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.55 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure
Basic EPS$ per share(0.73)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.73 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-05, accession 0000950170-24-121439.Report this figurenot reported(0.85)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.85 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-05, accession 0000950170-25-063518.Report this figure(0.80)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.80 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-04, accession 0000950170-25-101985.Report this figure(0.98)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.98 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figurenot reported(0.98)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.98 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure(0.83)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.83 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure(0.70)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.70 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figurenot reported(0.48)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.48 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure(0.55)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.55 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure

Balance sheet

Cash and equivalents$336.5m, Q2 FY2026
Shareholders' equity$15.1m, Q2 FY2026
Syndax Pharmaceuticals Inc, balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m94.6Cash and equivalents, Q3 FY2023, at 2023-09-30$94.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-02, accession 0000950170-23-058165.Report this figure295Cash and equivalents, FY2023, at 2023-12-31$295.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-26, accession 0001193125-26-076536.Report this figure115Cash and equivalents, Q1 FY2024, at 2024-03-31$114.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-08, accession 0000950170-24-055053.Report this figure105Cash and equivalents, Q2 FY2024, at 2024-06-30$105.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-01, accession 0000950170-24-089241.Report this figure133Cash and equivalents, Q3 FY2024, at 2024-09-30$133.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-05, accession 0000950170-24-121439.Report this figure154Cash and equivalents, FY2024, at 2024-12-31$154.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-26, accession 0001193125-26-076536.Report this figure154Cash and equivalents, Q1 FY2025, at 2025-03-31$154.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-05, accession 0000950170-25-063518.Report this figure109Cash and equivalents, Q2 FY2025, at 2025-06-30$108.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-04, accession 0000950170-25-101985.Report this figure117Cash and equivalents, Q3 FY2025, at 2025-09-30$116.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure135Cash and equivalents, FY2025, at 2025-12-31$134.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure131Cash and equivalents, Q1 FY2026, at 2026-03-31$130.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure336Cash and equivalents, Q2 FY2026, at 2026-06-30$336.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure
Current assets$m381Current assets, Q3 FY2023, at 2023-09-30$381.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-02, accession 0000950170-23-058165.Report this figure581Current assets, FY2023, at 2023-12-31$580.9m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-03, accession 0000950170-25-030394.Report this figure454Current assets, Q1 FY2024, at 2024-03-31$453.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-08, accession 0000950170-24-055053.Report this figure446Current assets, Q2 FY2024, at 2024-06-30$446.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-01, accession 0000950170-24-089241.Report this figure415Current assets, Q3 FY2024, at 2024-09-30$414.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-05, accession 0000950170-24-121439.Report this figure603Current assets, FY2024, at 2024-12-31$603.1m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-26, accession 0001193125-26-076536.Report this figure549Current assets, Q1 FY2025, at 2025-03-31$548.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-05, accession 0000950170-25-063518.Report this figure532Current assets, Q2 FY2025, at 2025-06-30$531.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-04, accession 0000950170-25-101985.Report this figure530Current assets, Q3 FY2025, at 2025-09-30$529.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure528Current assets, FY2025, at 2025-12-31$528.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure471Current assets, Q1 FY2026, at 2026-03-31$471.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure675Current assets, Q2 FY2026, at 2026-06-30$675.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure
Total assets$m399Total assets, Q3 FY2023, at 2023-09-30$399.2m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-02, accession 0000950170-23-058165.Report this figure613Total assets, FY2023, at 2023-12-31$612.9m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-03, accession 0000950170-25-030394.Report this figure543Total assets, Q1 FY2024, at 2024-03-31$543.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-08, accession 0000950170-24-055053.Report this figure477Total assets, Q2 FY2024, at 2024-06-30$476.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-01, accession 0000950170-24-089241.Report this figure426Total assets, Q3 FY2024, at 2024-09-30$425.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-05, accession 0000950170-24-121439.Report this figure725Total assets, FY2024, at 2024-12-31$724.8m. XBRL concept us-gaap:Assets. 10-K filed 2026-02-26, accession 0001193125-26-076536.Report this figure641Total assets, Q1 FY2025, at 2025-03-31$640.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-05, accession 0000950170-25-063518.Report this figure596Total assets, Q2 FY2025, at 2025-06-30$596.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-04, accession 0000950170-25-101985.Report this figure552Total assets, Q3 FY2025, at 2025-09-30$551.8m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure530Total assets, FY2025, at 2025-12-31$529.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure473Total assets, Q1 FY2026, at 2026-03-31$472.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure704Total assets, Q2 FY2026, at 2026-06-30$703.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure
Current liabilities$m39.2Current liabilities, Q3 FY2023, at 2023-09-30$39.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-02, accession 0000950170-23-058165.Report this figure58.1Current liabilities, FY2023, at 2023-12-31$58.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-03, accession 0000950170-25-030394.Report this figure50.8Current liabilities, Q1 FY2024, at 2024-03-31$50.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-08, accession 0000950170-24-055053.Report this figure42.5Current liabilities, Q2 FY2024, at 2024-06-30$42.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-01, accession 0000950170-24-089241.Report this figure59.4Current liabilities, Q3 FY2024, at 2024-09-30$59.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-05, accession 0000950170-24-121439.Report this figure104Current liabilities, FY2024, at 2024-12-31$103.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-26, accession 0001193125-26-076536.Report this figure94.6Current liabilities, Q1 FY2025, at 2025-03-31$94.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-05, accession 0000950170-25-063518.Report this figure113Current liabilities, Q2 FY2025, at 2025-06-30$113.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-04, accession 0000950170-25-101985.Report this figure114Current liabilities, Q3 FY2025, at 2025-09-30$114.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure120Current liabilities, FY2025, at 2025-12-31$120.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure86.2Current liabilities, Q1 FY2026, at 2026-03-31$86.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure99.7Current liabilities, Q2 FY2026, at 2026-06-30$99.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure
Total liabilities$m40.0Total liabilities, Q3 FY2023, at 2023-09-30$40.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-02, accession 0000950170-23-058165.Report this figure58.7Total liabilities, FY2023, at 2023-12-31$58.7m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-03, accession 0000950170-25-030394.Report this figure51.1Total liabilities, Q1 FY2024, at 2024-03-31$51.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-08, accession 0000950170-24-055053.Report this figure42.6Total liabilities, Q2 FY2024, at 2024-06-30$42.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-01, accession 0000950170-24-089241.Report this figure59.4Total liabilities, Q3 FY2024, at 2024-09-30$59.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-05, accession 0000950170-24-121439.Report this figure437Total liabilities, FY2024, at 2024-12-31$436.7m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-26, accession 0001193125-26-076536.Report this figure426Total liabilities, Q1 FY2025, at 2025-03-31$425.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-05, accession 0000950170-25-063518.Report this figure439Total liabilities, Q2 FY2025, at 2025-06-30$438.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-04, accession 0000950170-25-101985.Report this figure436Total liabilities, Q3 FY2025, at 2025-09-30$436.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure465Total liabilities, FY2025, at 2025-12-31$465.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure431Total liabilities, Q1 FY2026, at 2026-03-31$431.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure689Total liabilities, Q2 FY2026, at 2026-06-30$688.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure
Current portion of debt$mnot reported0.0Current portion of debt, FY2023, at 2023-12-31$0. XBRL concept us-gaap:LongTermDebtCurrent. 10-K filed 2025-03-03, accession 0000950170-25-030394.Report this figurenot reportednot reportednot reported338Current portion of debt, FY2024, at 2024-12-31$337.9m. XBRL concept us-gaap:LongTermDebtCurrent. 10-K filed 2026-02-26, accession 0001193125-26-076536.Report this figure336Current portion of debt, Q1 FY2025, at 2025-03-31$335.9m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2025-05-05, accession 0000950170-25-063518.Report this figure331Current portion of debt, Q2 FY2025, at 2025-06-30$330.6m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2025-08-04, accession 0000950170-25-101985.Report this figure327Current portion of debt, Q3 FY2025, at 2025-09-30$327.1m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure350Current portion of debt, FY2025, at 2025-12-31$350.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure350Current portion of debt, Q1 FY2026, at 2026-03-31$350.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure350Current portion of debt, Q2 FY2026, at 2026-06-30$350.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure
Shareholders' equity$m359Shareholders' equity, Q3 FY2023, at 2023-09-30$359.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-05, accession 0000950170-24-121439.Report this figure554Shareholders' equity, FY2023, at 2023-12-31$554.2m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-26, accession 0001193125-26-076536.Report this figure492Shareholders' equity, Q1 FY2024, at 2024-03-31$491.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure434Shareholders' equity, Q2 FY2024, at 2024-06-30$434.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure366Shareholders' equity, Q3 FY2024, at 2024-09-30$366.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure288Shareholders' equity, FY2024, at 2024-12-31$288.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure215Shareholders' equity, Q1 FY2025, at 2025-03-31$215.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure157Shareholders' equity, Q2 FY2025, at 2025-06-30$157.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure115Shareholders' equity, Q3 FY2025, at 2025-09-30$115.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure64.6Shareholders' equity, FY2025, at 2025-12-31$64.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure41.6Shareholders' equity, Q1 FY2026, at 2026-03-31$41.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure15.1Shareholders' equity, Q2 FY2026, at 2026-06-30$15.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure

Cash flow

Operating cash flow−$30.3m, Q2 FY2026
Syndax Pharmaceuticals Inc, cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(44.7)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$44.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-05, accession 0000950170-24-121439. Derived: 9-month figure less the 6-month figure.Report this figure(41.3)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$41.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-076536. Derived: 12-month figure less the 9-month figure.Report this figure(83.5)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$83.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-05, accession 0000950170-25-063518.Report this figure(71.6)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$71.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-04, accession 0000950170-25-101985. Derived: 6-month figure less the 3-month figure.Report this figure(62.3)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$62.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-03, accession 0001193125-25-262521. Derived: 9-month figure less the 6-month figure.Report this figure(57.4)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$57.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-076536. Derived: 12-month figure less the 9-month figure.Report this figure(95.2)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$95.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure(87.8)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$87.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-04, accession 0001193125-26-332750. Derived: 6-month figure less the 3-month figure.Report this figure(70.5)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$70.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-03, accession 0001193125-25-262521. Derived: 9-month figure less the 6-month figure.Report this figure(69.5)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$69.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-076536. Derived: 12-month figure less the 9-month figure.Report this figure(50.3)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$50.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure(30.3)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$30.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-04, accession 0001193125-26-332750. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)88.99m, Q2 FY2026
Syndax Pharmaceuticals Inc, shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares60.7Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3060,670,294 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-02, accession 0000950170-23-058165.Report this figure69.4Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3169,438,890 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-08, accession 0000950170-24-055053.Report this figure69.6Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3069,638,427 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-01, accession 0000950170-24-089241.Report this figure69.9Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3069,855,766 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-05, accession 0000950170-24-121439.Report this figure85.2Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3185,213,200 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-05, accession 0000950170-25-063518.Report this figure85.3Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3085,274,829 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-04, accession 0000950170-25-101985.Report this figure85.4Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3085,433,569 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure86.2Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3186,171,889 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure86.3Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3086,337,237 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure86.6Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3086,620,992 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-03, accession 0001193125-25-262521.Report this figure88.3Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3188,255,636 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-04-30, accession 0001193125-26-197154.Report this figure89.0Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3088,991,317 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure

Shares outstanding: 89.30mShares outstanding, period not labelled, at 2026-07-3189,297,086 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-04, accession 0001193125-26-332750.Report this figure at Jul 31, 2026, from the cover of the 10-Q filed Aug 4, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. Listed shows no prices and gives no investment advice.